Immuno-Therapy in the Treatment of Cancer: Implications for Efficacy and Economic Evaluations

L'immunoterapia Nel Trattamento Del Cancro: Implicazioni Per Le Valutazioni Di Efficacia Ed Economiche

Authors

  • Claudio Jommi Cergas (Centro di Ricerche sulla Gestione dell'Assistenza Sanitaria e Sociale), Università Bocconi, Milano - Italy
  • Francesco S. Mennini Institute for Leadership and Management in Health, Kingston University London, London - UK
  • Pier L. Canonico Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara - Italy
  • Paolo Bruzzi IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro, Genova - Italy

DOI:

https://doi.org/10.33393/grhta.2016.401

Keywords:

Cancer immunotherapy, Clinical endpoints, Cost-effectiveness, Market access

Abstract

In the last few years, immuno-oncology has partially modified the paradigm of cancer treatment, due to the observation of long-term survivors among patients with advanced tumors and with a predicted limited life expectancy, if treated with immunotherapeutic agents. This paper illustrates the opinion of an expert panel (Scientific Board on Immuno-oncology and Cancer Treatment) regarding the clinical and economic assessments of immunologic anticancer treatments. The agreement on the document was reached through a Consensus Conference. Overall survival and/or survival rates at specific time-points are the ideal parameters to evaluate the efficacy and effectiveness of immunotherapies. Since benefits affect different patients at different times across cancer indications of immunotherapies, short-term (on most of targeted patients) and long-term effects on smaller groups should be considered. When market access decisions are taken, the benefit profile of immunotherapies has important implications for their economic assessment. Robust long-term extrapolation of expected survival rates should be carried out when cost-efficacy (effectiveness) of immunotherapies is estimated; mean instead of median incremental survival rate is a more appropriate measure; real-world data collection should be strengthened and used to eventually revise decisions taken on price and reimbursement.

Downloads

Published

2016-11-02

How to Cite

1.
Jommi C, Mennini FS, Canonico PL, Bruzzi P. Immuno-Therapy in the Treatment of Cancer: Implications for Efficacy and Economic Evaluations: L’immunoterapia Nel Trattamento Del Cancro: Implicazioni Per Le Valutazioni Di Efficacia Ed Economiche. Grhta [Internet]. 2016 Nov. 2 [cited 2022 Jul. 5];3(1):1-8. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/401

Most read articles by the same author(s)

1 2 > >>